Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Oct 09,2021
Medicilon Won Four Heavyweight Awards in One Fell Swoop!
On September 28, the list of "15th China Listed Company Value Selection", sponsored by Securities Times and specially co-organized by Caitong Securities, was officially announced.
More
Medicilon Won Four Heavyweight Awards in One Fell Swoop!
Oct 09,2021
Medicilon won the "Science and Innovation Golden Horse Excellent Company Award " at the 2021 Science and Technology Leaders Summit
On July 22, 2019, the Shanghai Sci-Tech Innovation Board (STAR) opened.  Two years later, on July 22, 2021, 313 companies are listed on the STAR. 
More
Medicilon won the "Science and Innovation Golden Horse Excellent Company Award " at the 2021 Science and Technology Leaders Summit
Sep 22,2021
Medicilon is Listed on the Top Chinese R&D CRO Enterprises in 2021
Shanghai Medicilon Inc. (Medicilon) was invited to participate in this event and was awarded the Top Chinese R&D CRO Enterprises in 2021 .
More
Medicilon is Listed on the Top Chinese R&D CRO Enterprises in 2021
Sep 22,2021
Medicilon attended the 21st China International Fair for Investment and Trade
Medicilon attended the 21st China International Fair for Investment and Trade and signed a strategic collaboration agreement with Xiamen Biotime. The 21st China International Fair
More
Medicilon attended the 21st China International Fair for Investment and Trade
Sep 22,2021
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
IL-23 is mainly produced by activated dendritic cells, macrophages and monocytes. It is a new member of the IL-12 heterodimeric cytokine family.
More
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
Sep 15,2021
The 19th Annual San Diego BioPharma Conference
Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg,
More
The 19th Annual San Diego BioPharma Conference
Sep 13,2021
Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award
Shanghai Medicilon Inc. (Medicilon) "Internet + One-Stop Preclinical R&D Service Platform" was awarded the "Science and Technology Innovation Service Demonstration Case” award.
More
Medicilon won the "Science and Technology Innovation Service Demonstration Case" Award
Sep 13,2021
Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department. Dr. Hong
More
Medicilon appoints Dr. Hong Wan as Vice President of DMPK and Bioanalysis Department
Aug 19,2021
Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism
More
Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism
Aug 16,2021
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration
More
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Aug 16,2021
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at
More
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
Aug 13,2021
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Recently, Shanghai Ringene Biopharma (Ringene) announced that the company's self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical
More
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->